/
RGLS
$8.16+$0.02 (+0.25%)prev close
Change+$0.26
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Sector
Biotechnology
P/S (TTM)
1588
Regulus Therapeutics Inc.
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
www.novartis.com- Employees
- 34
- IPO / List date
- Oct 9, 2012
- HQ
- US
Held by traders on TradeandTell
No one on the platform currently holds RGLS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 147,900 | $258.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2022-06-29 | 1-for-10reverse |
| 2018-10-04 | 1-for-12reverse |
Recent trades on TradeandTell
No one on the platform has traded RGLS yet.
